Follicular lymphoma: 2012 update on diagnosis and management

@article{Freedman2012FollicularL2,
  title={Follicular lymphoma: 2012 update on diagnosis and management},
  author={Arnold S Freedman},
  journal={American Journal of Hematology},
  year={2012},
  volume={87}
}
  • A. Freedman
  • Published 1 October 2012
  • Medicine, Biology
  • American Journal of Hematology
Disease overview: Follicular lymphoma (FL) is generally an indolent B‐cell lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by diffuse lymphoadenopathy, involvement of bone marrow, splenomegaly, and less commonly other extranodal sites of involvement. In general, cytopenias can occur but constitutional symptoms of fever, nightsweats, and weight loss are uncommon. 
View on Wiley
onlinelibrary.wiley.com
50 Citations
Highly Influential Citations
6
Background Citations
20
Results Citations
1

50 Citations

Hematologic malignancies of the pancreas
TLDR
The clinical and imaging features of pancreatic lymphoma, pancreatic extraosseous multiple myeloma, granulocytic sarcoma (chloroma), posttransplant lymphoproliferative disorder, and Castleman disease are discussed.
INSIGHT INTO THE PATHOGENESIS OF FOLLICULAR LYMPHOMA
TLDR
Understanding of biology, pathological clinical course and management of Follicular lymphoma, both in inductions as well as in maintenance therapy, is summarized.
Rapidly Progressed Primary Intestinal Follicular Lymphoma with Elevation of Soluble Interleukin-2 Receptor Levels
TLDR
A case of rapidly progressed intestinal follicular lymphoma is illustrated, suggesting the possible usefulness of sIL-2R levels as an indicator of lymphoma progression.
Defining clinically relevant subgroups of follicular lymphoma cases according to the functional status of the CDKN2A gene
Thesis (Ph.D, Pathology & Molecular Medicine) -- Queen's University, 2013-03-12 23:49:44.541
Oral follicular lymphomas. A short report of 8 cases with assessment of the IGH/BCL2 gene fusion with fluorescence in situ hybridization.
High-Dose Chemotherapy for Relapsed Follicular Lymphoma Grade 3 B with Deletions of Loci of BCL 6 ( 3 q 27 ) and TP 53 ( 17 p 13 ) Genes : Case Report and Literature Review
TLDR
A rare case of grade 3B FL with a nodulardiffuse growth and a high Ki-67 level, and the unique ability of bendamustine to induce ТР53-independent apoptosis offers new opportunities for the high-dose chemotherapy of lymphomas, which seems promising.
Trends in excess mortality in follicular lymphoma at a population level
TLDR
Since the 1990s and since the development of humanised monoclonal antibodies in 1998, the treatment of non‐Hodgkin lymphoma has undergone profound changes, and several clinical trials have shown a significant improvement in overall survival.
A case of surgical treatment for primary BCL2-“negative” follicular lymphoma without t(14;18) in early stage of the submandibular lymph node
A case of primary pancreatic non-Hodgkin B-cell lymphoma mimicking autoimmune pancreatitis.
TLDR
A case of primary pancreatic lymphoma is reported in a young woman with jaundice, fever and abdominal pain mimicking autoimmune pancreatitis that revealed a large duodenal mass.
Treatment of Adolescents with Aggressive B-Cell Malignancies: The Pediatric Experience
TLDR
Current data on patient characteristics, biology, treatment and outcome, mainly in pediatric patients are compared to those published for adult patients with B-cell NHL aiming to look for hints on optimal classification and treatment in adolescents and young adults with B.NHL.
...
...

References

SHOWING 1-10 OF 114 REFERENCES
Treatment of follicular non-Hodgkin's lymphoma: the old and the new.
TLDR
Despite remaining an incurable disease, overall survival improvements have been noted in patients with advanced-stage follicular lymphoma and the FLIPI is a robust prognostic index in this disease, and continues to provide prognostic information in the rituximab era.
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma
The combination of fludarabine, cyclophosphamide, and rituximab (FC‐R) shows significant in vitro synergism and may improve patient outcome with little overlapping toxicity.
Prognosis in follicular lymphoma--it's in the microenvironment.
  • R. Küppers
  • Medicine, Biology
    The New England journal of medicine
  • 2004
TLDR
A large number of markers that predict the clinical behavior of B-cell lymphomas are still poorly understood, and further research is needed to understand why these markers are so poorly understood.
Improved survival in patients with early stage low‐grade follicular lymphoma treated with radiation
TLDR
External beam radiation therapy is the standard treatment for stage I‐II, grade 1‐2 follicular lymphoma and the relative improvement in outcomes for patients treated with and without RT has never been tested in randomized trials.
Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.
TLDR
With a median follow-up of 67 months, the 5-year survival is 72% and the failure-free survival (FFS) is 67%, with a possible plateau in the FFS curve, particularly for patients with stage I-III disease.
Transformation of indolent B-cell lymphomas.
  • S. Montoto, J. Fitzgibbon
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
It is crucial to incorporate HT as a major end point in clinical trials and to include patients with HT as subject of such studies if the authors are to see meaningful progress in the future.
Prognostic factors in follicular lymphoma.
TLDR
There is a need for useful biomarkers for prediction of the disease course of single patients to individualize therapy, especially in the new era of chemoimmunotherapy.
Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases.
TLDR
These findings characterize primary FL-D as a remarkably indolent FL variant, which, even left untreated, does not develop tumorous growth, very rarely disseminates and does not transform to high grade disease.
Long‐term responses in patients with recurring or refractory B‐cell non‐Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non‐Hodgkin lymphoma (NHL), but the durability of those remissions is not…
Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group.
  • J. Anderson, J. Vose, J. Armitage
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
A proportion of stage I/II FLCL patients may obtain long-term disease control with combination chemotherapy plus radiotherapy and significantly poorer survival was only seen in patients older than 70 years of age.
...
...